Business
Nektar Therapeutics Reports First Quarter 2026 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.","length":164,"tagName":"p"},{"type":"image","alt":"Nektar Logo (PRNewsfoto/Nektar Therapeutics)","displaySize":"","headline":null,"caption":"Nektar Logo (PRNewsfoto/Nektar Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":145,"url":"https://media.zenfs.com/en/prnewswire.com/e9141883926ab6553b7ec849fd9c6537"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0s2k54me9FiZs8HTjKisRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1Ng--/https://media.zenfs.com/en/prnewswire.com/e9141883926ab6553b7ec849fd9c6537","width":400,"height":145}},"href":"https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025. Nektar's cash and marketable securities at March 31, 2026, exclude net proceeds of approximately $351 million from the secondary offering completed by the Company on April 23, 2026.","length":362,"tagName":"p"},{"type":"text","content":""2026 is shaping up to be a defining year for Nektar and for our lead biologic candidate rezpegaldesleukin," said Howard W. Robin, President and Chief Executive Officer of Nektar. "We have now shown that longer-term treatment with rezpegaldesleukin continues to deepen clinical responses in two distinct immune-mediated diseases, reinforcing our belief that this novel Treg mechanism can transform the treatment paradigm for autoimmune disease. The Phase 3 ZENITH-AD program in atopic dermatitis will initiate by July, and we will have our End-of-Phase 2 meeting for alopecia areata this quarter. With a substantially strengthened balance sheet and over one billion dollars in cash and investments, we are well positioned to advance rezpegaldesleukin into late-stage development with strong scientific and clinical conviction."","length":847,"tagName":"p"},{"type":"text","content":"Revenue in the first quarter of 2026 was $10.9 million as compared to $10.5 million in the first quarter of 2025.","length":133,"tagName":"p"},{"type...